Pan African Consortium for the Evaluation of Antituberculosis Antibiotics
The consortium brings together a group of scientists from more than 14 countries with skills in clinical trials design and implementation, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service. At 911±¬ÁÏÍø the team includes Professor Tim McHugh, director of the Centre for Clinical Microbiology, and Dr Patrick Phillips and Ms Sunita Rehal at the MRC-UCL Clinical Trials Unit.
PanACEA's mission is:
- To shorten and simplify treatment of uncomplicated pulmonary TB
- To increase the TB clinical trial capacity in Africa
- To develop sustainable TB clinical trials network in Africa
At the annual Conference on Retroviruses and Opportunistic Infections (CROI), PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics, presented the results of its most recent phase IIb study (MAMS-TB-01). The most exciting finding from the study is that high-dose rifampicin results in faster killing of TB bacilli during treatment, compared to the current standard treatment. You can read more about this exciting development here.